A federal appeals court has significantly restricted access to the abortion pill mifepristone by blocking its distribution through the mail. According to multiple reports, a panel of the New Orleans-based Fifth Circuit Court of Appeals ruled that the drug must now be distributed only in person at clinics.
Key Takeaways
A federal appeals court has restricted access to the abortion pill mifepristone by blocking mail-order prescriptions. The ruling requires the drug to be distributed only in person at clinics.
- Fifth Circuit Court of Appeals issues order restricting mifepristone distribution
- Ruling affects states with abortion bans and telemedicine prescriptions nationwide
- FDA's 2023 regulation allowing mail-order mifepristone is paused
- Decision likely to be appealed to the Supreme Court
The ruling stems from a lawsuit brought by Louisiana, which argued that allowing mifepristone to be mailed into the state undermines its ban on abortion. The court agreed, stating that 'every abortion facilitated by FDA's action cancels Louisiana's ban on medical abortions and undermines its policy that every unborn child is a human being from the moment of conception,' as reported by BBC.
The decision affects access to medication abortion, the most common method of terminating pregnancies in the U.S. According to CBS News, since the Supreme Court's 2022 ruling that overturned Roe v. Wade, prescriptions by mail have become a major way that abortions are provided, including in states where bans are in place.
The court's order pauses a 2023 regulation from the Food and Drug Administration (FDA) that allowed doctors to send mifepristone without seeing patients in person. The FDA had lifted the in-person dispensing requirement for mifepristone during the COVID-19 pandemic, making it possible for the medication to be sent by mail.
Reactions to the ruling have been mixed. Julia Kaye of the American Civil Liberties Union (ACLU) criticized the decision, stating that 'for countless people, especially those who live in rural areas, face intimate partner violence, or live with disabilities, losing a telemedicine option will mean losing access to this vital medication altogether,' as reported by BBC. Meanwhile, Louisiana Attorney General Liz Murrill celebrated the court's decision, according to HuffPost.
The ruling is likely to be appealed to the Supreme Court. In 2024, the high court unanimously rejected an effort to restrict access to mifepristone but left the door open for other attempts to limit its availability, as noted by NPR. The decision sets up a potential legal battle over abortion access in the U.S.
How this summary was created
This summary synthesizes reporting from 6 independent publishers using AI. All sources are cited and linked below. NewsBalance is a news aggregator and media literacy tool, not a news publisher. AI-generated content may contain errors or inaccuracies — always verify important information with the original sources.